Zoledronic Acid News and Research

RSS
Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis medication Aclasta now available on Canadian public drug plans

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Osteoporosis drug protects against bone damaging side effects of breast cancer medications

Osteoporosis drug protects against bone damaging side effects of breast cancer medications

Zoledronic acid may extend survival in older breast cancer patients

Zoledronic acid may extend survival in older breast cancer patients

Zoledronic acid may benefit post-menopausal women with breast cancer

Zoledronic acid may benefit post-menopausal women with breast cancer

Zometa bone drug trial in post-menopausal women with breast cancer

Zometa bone drug trial in post-menopausal women with breast cancer

IRSF announces new Rett syndrome translational research awards

IRSF announces new Rett syndrome translational research awards

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases